20.02
price down icon5.43%   -1.15
pre-market  Pre-market:  20.04   0.02   +0.10%
loading
Intellia Therapeutics Inc stock is currently priced at $20.02, with a 24-hour trading volume of 1.43M. It has seen a -5.43% decreased in the last 24 hours and a -25.38% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $21.31 pivot point. If it approaches the $20.19 support level, significant changes may occur.
Previous Close:
$21.17
Open:
$20.53
24h Volume:
1.43M
Market Cap:
$1.92B
Revenue:
$36.28M
Net Income/Loss:
$-481.19M
P/E Ratio:
-3.6667
EPS:
-5.46
Net Cash Flow:
$-408.07M
1W Performance:
-6.10%
1M Performance:
-25.38%
6M Performance:
-17.88%
1Y Performance:
-44.80%
1D Range:
Value
$19.64
$20.66
52W Range:
Value
$19.64
$47.48

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name
Name
Intellia Therapeutics Inc
Name
Phone
857-285-6200
Name
Address
40 Erie Street, Suite 130, Cambridge, MA
Name
Employee
195
Name
Twitter
@intelliatweets
Name
Next Earnings Date
2024-05-02
Name
Latest SEC Filings
Name
NTLA's Discussions on Twitter

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-15-24 Initiated Wolfe Research Peer Perform
Apr-13-23 Initiated Canaccord Genuity Buy
Mar-21-23 Initiated Bernstein Outperform
Mar-14-23 Upgrade BMO Capital Markets Market Perform → Outperform
Feb-01-23 Initiated Cantor Fitzgerald Overweight
Jan-24-23 Upgrade Citigroup Sell → Neutral
Jan-19-23 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Oct-11-22 Initiated Morgan Stanley Overweight
Sep-21-22 Initiated JP Morgan Overweight
Sep-01-22 Initiated Citigroup Sell
Jun-17-22 Initiated BMO Capital Markets Market Perform
Jun-16-22 Initiated BofA Securities Buy
Apr-28-22 Initiated Credit Suisse Outperform
Feb-18-22 Initiated William Blair Outperform
Feb-07-22 Upgrade Oppenheimer Perform → Outperform
Jan-31-22 Initiated Cowen Outperform
Jan-07-22 Initiated Piper Sandler Overweight
Oct-05-21 Initiated Guggenheim Buy
Sep-24-21 Initiated Stifel Buy
Jun-28-21 Reiterated H.C. Wainwright Buy
Jun-11-21 Initiated H.C. Wainwright Buy
May-07-21 Upgrade ROTH Capital Neutral → Buy
May-04-21 Initiated RBC Capital Mkts Outperform
Mar-04-21 Initiated JMP Securities Mkt Outperform
Dec-22-20 Downgrade Robert W. Baird Outperform → Neutral
Oct-27-20 Initiated Truist Buy
Oct-14-20 Initiated Wells Fargo Overweight
Sep-18-20 Initiated Goldman Buy
Feb-28-20 Upgrade Oppenheimer Perform → Outperform
Feb-14-20 Downgrade Wedbush Outperform → Neutral
Nov-01-19 Upgrade Raymond James Mkt Perform → Outperform
Jul-09-19 Initiated Robert W. Baird Outperform
Jun-10-19 Initiated ROTH Capital Neutral
May-03-19 Upgrade Wedbush Neutral → Outperform
Apr-12-19 Initiated Evercore ISI Outperform
Nov-02-18 Downgrade Wedbush Outperform → Neutral
Oct-29-18 Initiated Credit Suisse Neutral
Sep-21-18 Initiated Raymond James Mkt Perform
May-15-18 Upgrade Chardan Capital Markets Neutral → Buy
Mar-08-18 Initiated JMP Securities Mkt Outperform
Nov-01-17 Reiterated Jefferies Buy
Jun-22-17 Resumed Jefferies Buy
Mar-28-17 Initiated Chardan Capital Markets Buy
Aug-05-16 Upgrade Jefferies Hold → Buy
View All

Intellia Therapeutics Inc Stock (NTLA) Financials Data

Intellia Therapeutics Inc (NTLA) Revenue 2024

NTLA reported a revenue (TTM) of $36.27 million for the quarter ending December 31, 2023, a -30.40% decline year-over-year.
loading

Intellia Therapeutics Inc (NTLA) Net Income 2024

NTLA net income (TTM) was -$481.19 million for the quarter ending December 31, 2023, a -1.48% decrease year-over-year.
loading

Intellia Therapeutics Inc (NTLA) Cash Flow 2024

NTLA recorded a free cash flow (TTM) of -$408.07 million for the quarter ending December 31, 2023, a -4.19% decrease year-over-year.
loading

Intellia Therapeutics Inc (NTLA) Earnings per Share 2024

NTLA earnings per share (TTM) was -$5.41 for the quarter ending December 31, 2023, a +12.46% growth year-over-year.
loading
Intellia Therapeutics, Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; and partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
$148.56
price up icon 3.08%
$82.17
price down icon 9.90%
$27.46
price down icon 3.55%
$143.71
price down icon 0.06%
$86.71
price down icon 1.57%
$368.60
price down icon 1.71%
Cap:     |  Volume (24h):